In accordance with this model, our analysis of human serum samples revealed no changes in eotaxin levels in FSHD patients and excluded eotaxin as a potential circulating biomarker for FSHD. This evidence concerns the gene CCL11 and facioscapulohumeral muscular dystrophy.